featured
Ruxolitinib vs Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
J. Clin. Oncol 2023 May 01;[EPub Ahead of Print], CN Harrison, J Nangalia, R Boucher, A Jackson, C Yap, J O'Sullivan, S Fox, I Ailts, AC Dueck, HL Geyer, RA Mesa, WG Dunn, E Nadezhdin, N Curto-Garcia, A Green, B Wilkins, J Coppell, J Laurie, M Garg, J Ewing, S Knapper, J Crowe, F Chen, I Koutsavlis, A Godfrey, S Arami, M Drummond, J Byrne, F Clark, C Mead-Harvey, EJ Baxter, MF McMullin, AJ MeadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.